A S100A9-binding small molecule (ABR-215050) that inhibits the interaction between S100A9 and TLR4, the major receptor required for chemically-induced oral carcinogenesis [41], is presently in Phase III clinical trial for treating prostate cancer [42]. This evidence concerns the gene S100A9 and Familial prostate cancer.